Key result
MI in HFmrEF is linked to ~40% lower mortality, largely mediated by PCI.
Why the study?
Relatively few studies have examined patients with HFmrEF after MI, and the prognosis of such patients remains unclear.
Does a history of myocardial infarction affect all-cause mortality and cardiovascular events in patients with HFmrEF?
Cohort (n=1,691)
No
Does a history of myocardial infarction affect all-cause mortality and cardiovascular events in patients with HFmrEF?
In patients with HFmrEF, a history of myocardial infarction does not independently worsen all-cause mortality or cardiovascular events when accounting for the protective effect of percutaneous coronary intervention (PCI).
Answers are grounded in this paper and cite their sources.
MI history is not an independent mortality risk in HFmrEF after PCI adjustment; leaves open causal effects in observational cohorts.
Background: Clinical studies on heart failure (HF) with mildly reduced left ventricular ejection fraction (HFmrEF) are gradually increasing. However, relatively few studies have examined patients with HFmrEF after myocardial infarction (MI), and the prognosis of such patients remains unclear. Therefore, we conducted a retrospective evaluation of HFmrEF patients with/without MI using a propensity score matching analysis (PSMA). Methods: A total of 1,691 patients with HFmrEF were included in this study. Of these patients, 873 had a diagnosis of MI, and 818 did not. After propensity score matching, we used Kaplan-Meier analysis and Cox regression to compare all-cause mortality, cardiovascular death, or HF readmission (CV events). Results: After the first PSMA, the MI group had a lower risk of all-cause mortality [hazard ratio (HR) 0.6; 95% confidence interval (95% CI) 0.5-0.8] compared with the non-MI group; however, there was no significant difference in the incidence of CV events (HR 0.9; 95% CI 0.7-1.2). After the second PSMA, which additionally matched for PCI performance in the MI group, there were no differences in the risk of all-cause mortality (HR 1.0; 95% CI 0.7-1.5) or CV events (HR 1.1; 95% CI 0.8-1.5) between the MI and non-MI groups. Conclusions: There was no difference in all-cause mortality and CV events between patients with HFmrEF with and without MI. However, among patients with HFmrEF and MI, those who underwent PCI had a much lower risk of all-cause mortality compared with patients with HFmrEF without MI and those with HFmrEF after MI who did not undergo PCI.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) conducted a cohort in Heart failure with mildly reduced ejection fraction (HFmrEF) (n=1,691). Myocardial infarction (MI) vs. No myocardial infarction (non-MI) was evaluated on All-cause mortality (HR 0.6, 95% CI 0.5-0.8, p=<0.001). Patients with HFmrEF and myocardial infarction had a lower risk of all-cause mortality compared to those without MI (HR 0.6), a protective effect that was largely mediated by percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: